How does it work?

Each RAPID MAX™ kit comes with a 96-well strip plate that has been pre-coated to immobilize the biotinylated capture antibody, removing the need for long incubations to coat the plate. Standards and samples can be added directly to the well. Unlike a typical sandwich ELISA, the RAPID MAX™ workflow only contains a single one-hour antibody incubation. In this step, the biotinylated capture and HRP-conjugated detection antibody bind to the protein of interest in solution. Next, the plates are washed and incubated with substrate. Finally, stop solution is added, and the plate can be read on an appropriate device.

Traditional ELISA workflows can take nearly 24 hours, including overnight plate coating. Even with pre-coated plates, the process can still take upwards of 4 hours. By simplifying the workflow, RAPID MAX™ kits reduce the total assay time to 90 minutes or less.

 

Figure 1. Comparison of the RAPID MAX™ and traditional ELISA workflows.
 

How are RAPID MAX™ kits validated?

Each kit is fully validated using relevant biological samples, including EDTA plasma, citrate plasma, heparin plasma, serum, and cell culture supernatant. We also test the following parameters and include the results in the user manuals (available on the product webpage).

• Specificity and cross-reactivity of the antibodies
• Sensitivity
• Spike Recovery
• Linearity of Dilution
• Inter/Intra-Assay Precision

 

Below, we show validation data for our RAPID MAX™ Human IL-6 Kit. Spike recovery experiments (shown on the left) are performed by ‘spiking’ recombinant target proteins into a variety of sample types. These experiments help determine whether matrix effects are interfering with the reading. Linearity of dilution experiments help to confirm that results are dose-responsive and that the assay will work over a range of concentrations. For these experiments, human samples were diluted to the recommended dilution factor, spiked with a high concentration of IL-6, and then further diluted to produce samples within the dynamic range of the assay.  

 

 

Figure 2: Left: Recombinant IL-6 was added at different concentrations to indicated samples. Samples were analyzed using the RAPID MAX™ Human IL-6 ELISA Kit. The percent recovery was calculated and averaged from n=4 samples. Right: Samples were diluted to the recommended dilution factor, spiked with recombinant IL-6, and further diluted in a series of 2-fold dilutions. The percent linearity ≥3 samples was averaged for each sample type.
 

How does RAPID MAX™ compare to other ELISA formats?

RAPID MAX™ kits get data faster without compromising on quality and offer comparable results to our ELISA kits and sets. During development, our RAPID MAX™ kits are run in a side-by-side experiment with other kit formats to ensure that the results are consistent.

 

 

Figure 3: Human IL-6 was quantified in serum, EDTA plasma, and citrate plasma samples using either our LEGEND MAX™ or RAPID MAX™ kit formats to confirm that both kits provide similar results.
 

Figure 4: Human IL-6 was quantified in serum and cell culture supernatant using the RAPID MAX™ ELISA kit (BioLegend) or an equivalent kit from a competitor. Samples were spiked with recombinant IL-6 and diluted to produce samples within the dynamic range.